IMUNON Inc. (IMNN), a clinical-stage biotechnology company, last week announced a positive recommendation from an Independent Data Monitoring Committee (IDMC) regarding Phase 2 minimal residue disease (MRD) trial for IMNN-001 in ovarian cancer.
IMUNON Reports Positive IDMC Opinion For IMNN-001 In Ovarian Cancer
